A5029783882- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Immunotherapy and Immune Responses
- Cancer Genomics and Diagnostics
- Virus-based gene therapy research
- Cutaneous Melanoma Detection and Management
- Melanoma and MAPK Pathways
- Lung Cancer Treatments and Mutations
- Head and Neck Cancer Studies
- Renal cell carcinoma treatment
- Nonmelanoma Skin Cancer Studies
- Genetic factors in colorectal cancer
- Cancer Research and Treatments
- Colorectal and Anal Carcinomas
- Colorectal Cancer Treatments and Studies
- Salivary Gland Tumors Diagnosis and Treatment
- Immune Cell Function and Interaction
- Lung Cancer Diagnosis and Treatment
- Ferroptosis and cancer prognosis
- Computational Drug Discovery Methods
- Multiple and Secondary Primary Cancers
- CRISPR and Genetic Engineering
- Cancer-related Molecular Pathways
- Polyomavirus and related diseases
- Prostate Cancer Treatment and Research
University of California, San Diego
2016-2025
UC San Diego Health System
2014-2024
Moores Cancer Center
2013-2024
University of California, San Francisco
2021
Princess Margaret Cancer Centre
2017
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
2017
European Institute of Oncology
2017
Université Paris Cité
2017
Georgetown Lombardi Comprehensive Cancer Center
2017
Huntsman Cancer Institute
2015-2016
Nivolumab plus ipilimumab or nivolumab alone resulted in longer progression-free and overall survival than a trial involving patients with advanced melanoma. We now report 5-year outcomes the trial.
Talimogene laherparepvec (T-VEC) is a herpes simplex virus type 1-derived oncolytic immunotherapy designed to selectively replicate within tumors and produce granulocyte macrophage colony-stimulating factor (GM-CSF) enhance systemic antitumor immune responses. T-VEC was compared with GM-CSF in patients unresected stage IIIB IV melanoma randomized open-label phase III trial.Patients injectable that not surgically resectable were randomly assigned at two-to-one ratio intralesional or...
Immunotherapy induces durable responses in a subset of patients with cancer. High tumor mutational burden (TMB) may be response biomarker for PD-1/PD-L1 blockade tumors such as melanoma and non-small cell lung cancer (NSCLC). Our aim was to examine the relationship between TMB outcome diverse cancers treated various immunotherapies. We reviewed data on 1,638 who had undergone comprehensive genomic profiling assessment. Immunotherapy-treated (N = 151) were analyzed rate (RR), progression-free...
Treatment options for metastatic melanoma are limited. We conducted this phase II trial to assess the efficacy of JS1/34.5-/47-/granulocyte-macrophage colony-stimulating factor (GM-CSF) in stages IIIc and IV disease.Treatment involved intratumoral injection up 4 mL 10(6) pfu/mL JS1/34.5-/47-/GM-CSF followed 3 weeks later by 10(8) every 2 24 treatments. Clinical activity (by RECIST [Response Evaluation Criteria Solid Tumors]), survival, safety parameters were monitored.Fifty patients (stages...
In the phase III CheckMate 067 trial, durable clinical benefit was demonstrated previously with nivolumab plus ipilimumab and alone versus ipilimumab. Here, we report 6.5-year efficacy safety outcomes.Patients untreated unresectable stage or IV melanoma were randomly assigned 1:1:1 to receive 1 mg/kg 3 once every weeks (four doses) followed by 2 (n = 314), 316), doses; n 315). Coprimary end points progression-free survival overall (OS) Secondary included objective response rate, descriptive...
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Cutaneous melanoma have been significantly revised over the past few years response to emerging data on immune checkpoint inhibitor therapies and BRAF-targeted therapy. This article summarizes rationale supporting extensive changes recommendations systemic therapy as adjuvant treatment of resected disease unresectable or distant metastatic disease.
This selection from the NCCN Guidelines for Merkel Cell Carcinoma (MCC) focuses on areas impacted by recently emerging data, including sections describing MCC risk factors, diagnosis, workup, follow-up, and management of advanced disease with radiation systemic therapy. Included in these are discussion new recommendations use cell polyomavirus as a biomarker checkpoint immunotherapies to treat metastatic or unresectable disease. The next update complete version will include more detailed...
This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Melanoma focuses on adjuvant therapy and treatment of in-transit disease, because substantial changes were made to recommendations 2016 update. Depending stage options now include biochemotherapy high-dose ipilimumab. Treatment disease intralesional injection with talimogene laherparepvec (T-VEC), a new immunotherapy. These additions prompted re-assessment data supporting older recommended resulting...
Abstract PD-1 inhibitors are approved for treating advanced melanoma, but resistance has been observed. This phase Ib trial evaluated intratumoral SD-101, a synthetic CpG oligonucleotide that stimulates Toll-like receptor 9 (TLR9), in combination with pembrolizumab patients unresectable or metastatic malignant melanoma. The most common adverse events related to SD-101 were injection-site reactions and transient, mild-to-moderate “flu-like” symptoms. Among the naïve anti–PD-1 therapy, overall...
Purpose The addition of nivolumab (anti-programmed death-1 antibody) to ipilimumab (anti-cytotoxic T-cell lymphocyte-associated 4 in patients with advanced melanoma improves antitumor response and progression-free survival but a higher frequency adverse events (AEs). This cross-melanoma study describes the safety profile approved plus regimen. Methods retrospective review on data from three trials (phase I, II, III) included who received at least one dose 1 mg/kg 3 every weeks × then 2 until...
Basal cell carcinoma (BCC) of the skin is most common cancer, with a higher incidence than all other malignancies combined. Although it rare to metastasize, patients multiple or frequently recurring BCC can suffer substantial comorbidity and be difficult manage. Assessment risk key element management needed inform treatment selection. The overall primarily consists surgical approaches, radiation therapy as an alternate adjuvant option. Many superficial therapies for have been explored...
Abstract Purpose: Tumor mutational burden detected by tissue next-generation sequencing (NGS) correlates with checkpoint inhibitor response. However, biopsy may be costly and invasive. We sought to investigate the association between hypermutated blood-derived circulating tumor DNA (ctDNA) Experimental Design: assessed 69 patients diverse malignancies who received inhibitor–based immunotherapy ctDNA NGS testing (54–70 genes). Rates of stable disease (SD) ≥6 months, partial complete response...
Abstract Objective. DNA sequencing tests are enabling physicians to interrogate the molecular profiles of patients’ tumors, but most oncologists have not been trained in advanced genomics. We initiated a tumor board provide expert multidisciplinary input for these patients. Materials and Methods. A team that included clinicians, basic scientists, geneticists, bioinformatics/pathway scientists with expertise various cancer types attended. Molecular were performed Clinical Laboratory...
Abstract By profiling their patients' tumors, oncologists now have the option to use molecular results match patients with drug(s) based on specific biomarkers. In this observational study, 347 solid advanced cancers and next-generation sequencing (NGS) were evaluated. Outcomes for who received a “matched” versus “unmatched” therapy following NGS compared. Eighty-seven (25%) treated therapy, 93 (26.8%) an therapy. More in matched group achieved stable disease (SD) ≥ 6 months/partial response...
<h3>Background</h3> Metastatic melanoma (mM) and renal cell carcinoma (mRCC) are often treated with anti-PD-1 based therapy, however not all patients respond further therapies needed. High dose interleukin-2 (HD IL-2) can lead to durable responses in a subset of mM mRCC patients. The efficacy toxicity HD IL-2 therapy following or anti-PD-L1 have yet been explored. <h3>Methods</h3> Reports on who had received after PD-1 PD-L1 inhibition were queried from the PROCLAIM<sup>SM</sup> database....
Purpose: Preclinical models have shown that the effectiveness of GL-ONC1, a modified oncolytic vaccinia virus, is enhanced by radiation and chemotherapy. The purpose this study was to determine safety GL-ONC1 when delivered intravenously with chemoradiotherapy patients primary, nonmetastatic head neck cancer.Experimental Design: Patients locoregionally advanced unresected, carcinoma head/neck, excluding stage III-IVA p16-positive oropharyngeal cancers, were treated escalating doses cycles...
The NCCN Guidelines for Melanoma have been significantly revised over the past few years in response to emerging data on a number of novel agents and treatment regimens. These Insights summarize rationale supporting extensive changes recommendations systemic therapy patients with metastatic or unresectable melanoma.
High-dose interleukin-2 (HD IL-2) was approved for treatment of metastatic renal cell carcinoma (mRCC) in 1992 and melanoma (mM) 1998, an era predating targeted therapies immune checkpoint inhibitors. The PROCLAIMSM registry established to collect analyze data patients treated with HD IL-2 the current era. This analysis includes 170 mM 192 mRCC between 2005 2012 survival as July 27, 2015. For mM, complete response (CR) observed 5 %, partial (PR) 10 stable disease (SD) 22 63 % had progressive...
Therapies that produce deep and durable responses in patients with metastatic melanoma are needed. This phase II cohort from the international, single-arm PIVOT-02 study evaluated CD122-preferential interleukin-2 pathway agonist bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) first-line melanoma.A total of 41 previously untreated stage III/IV received BEMPEG 0.006 mg/kg NIVO 360 mg once every 3 weeks for ≤ 2 years; 38 were efficacy-evaluable (≥ 1 postbaseline scan). Primary end points...
We evaluated the activity of intratumoral Coxsackievirus A21 (V937) in 57 patients with unresectable stage IIIC or IV melanoma.In this multicenter, open-label, phase II study, received up to a total V937 dose 3 × 108 TCID50 (50% tissue culture infectious dose) maximum 4.0-mL volume by injection. Ten sets injections were administered between days 1 and 127 (NCT01227551). Patients who had stable disease responding could continue treatment an extension study (NCT01636882). Response progression...
Oncogenic BRAF mutations are commonly found in advanced differentiated thyroid cancer (DTC), and reports have shown efficacy of inhibitors these tumors. We investigated the difference response between dabrafenib monotherapy + trametinib therapy patients with BRAF-mutated radioactive iodine refractory DTC.